Yttrium-90 Radioembolization for High-Risk Hepatocellular Adenomas: A Single-Institution Experience.

Authors

Nathan Ji, Alex Sher, Josh Kim, Bryan Pacheco, Brett Marinelli, Jenanan Vairavamurthy, Dan Shilo, Rajesh Patel, Rahul Patel, Vivian Bishay, Aaron Fischman, Francis Nowakowski, Robert Lookstein, Kirema Garcia-Reyes, Edward Kim

Published in

Journal of vascular and interventional radiology : JVIR. Pages 109114. Oct 05, 2026. Epub Oct 05, 2026.

Abstract

To evaluate the safety and efficacy of Yttrium-90 (Y-90) transarterial radioembolization (TARE) for the treatment of high-risk hepatocellular adenomas (HCAs) at a single tertiary care center.
A retrospective review was performed of all patients who underwent TARE for HCAs at a tertiary care center between 2010 and 2025. Clinical, laboratory, imaging, and safety data were collected for twelve patients with 22 HCAs included in the study. The primary endpoint was treatment-related adverse events (AEs) graded by CTCAE and SIR AE classification. The secondary endpoints included target and overall radiologic response assessed by mRECIST.1 Patients were followed up with MRI at 6 weeks, 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months. Median follow-up between Y-90 and latest imaging was 17.7 months, with an IQR of 12.9 [8.0-20.9] months.
Indications for treatment included symptomatic adenoma (5%, 1/22), risk of malignant transformation (100%, 22/22) and hemorrhage risk (50%, 11/22). Grade 1 AEs (nausea, fatigue, anorexia, diarrhea, abdominal and shoulder pain) occurred in 75% (9/12) of patients. No grade 2 or greater AEs occurred. The objective response rate (ORR) was 100% (20/20) (complete target lesion response [CR]: 85% (17/20), partial target lesion response [PR]: 15% (3/20)). No lesions ruptured, progressed, or recurred during follow-up.
In this single-institution experience, TARE was safe and demonstrated high short to intermediate-term ORRs in the treatment of high-risk hepatocellular adenomas. Larger prospective studies with longer duration of follow up are needed to confirm these findings.

PMID:
42833615
Bibliographic data and abstract were imported from PubMed on 06 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.